Detalles de la búsqueda
1.
Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.
J Rheumatol
; 51(5): 529-537, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38428964
2.
Associations of DMARDs with post-acute sequelae of COVID-19 in patients with systemic autoimmune rheumatic diseases: a prospective study.
Rheumatology (Oxford)
; 2023 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38070152
3.
Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.
Ann Rheum Dis
; 83(5): 680-682, 2024 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38199795
4.
Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease.
Semin Arthritis Rheum
; 64: 152312, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38056314
5.
Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.
Lancet Rheumatol
; 6(1): e21-e30, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38258675
6.
Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease.
Clin Rheumatol
; 2024 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38898318
7.
Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study.
medRxiv
; 2023 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37873462
Resultados
1 -
7
de 7
1
Próxima >
>>